Clinical Trial for Ripretinib
Studies have shown that if you have GIST with mutations in KIT exons 11 and 17/18, ripretinib may be a better option for second-line treatment than the standard sunitinib.
Studies have shown that if you have GIST with mutations in KIT exons 11 and 17/18, ripretinib may be a better option for second-line treatment than the standard sunitinib.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.
The FDA approved QINLOCKTM (ripretinib) for the treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior treatments for their GIST.
Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).
Breaking news in Targeted Oncology online today - A New Drug Application (NDA) for Ripretinib (DCC-2618) was submitted to FDA for treatment of GIST, by Deciphera.
Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]
Every Wednesday in 2024 will be dedicated to learning about the clinical trial process and to highlighting the groundbreaking clinical trials focused on gastrointestinal stromal tumors (GIST). We understand the importance of staying informed [...]
Clinical trials are the backbone of medical progress, serving as the driving force behind the development of new treatments and therapies. Understanding the details of these trials is crucial, as it empowers you [...]
In 2022, our theme, “It’s Time to Tell the Stories,” marked a significant milestone as we celebrated 20 years of non-profit service. See our 2022 Annual Report.
If you didn't find what you were looking for, try a new search!